Generic Name:
cariprazine
Project Status:
Complete
Therapeutic Area:
Schizophrenia
Manufacturer:
Allergan (an AbbVie Company).
Brand Name:
Vraylar
Project Line:
Reimbursement Review
Project Number:
SR0708-000
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the acute and long-term maintenance of schizophrenia in adults.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of schizophrenia in adults.
Recommendation Type:
Do not reimburse
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Procedural review: CADTH accepted a procedural review request from AbbVie Canada for the SR0708-000 Vraylar Canadian Drug Expert Committee (CDEC) final recommendation.
Status: Concluded.
Description: This matter was concluded following adjudication by a Procedural Review Panel (the “panel”). In its decision, the panel found that CADTH and CDEC acted in accordance with the Procedures for CADTH Reimbursement Reviews for the review of Vraylar.
The Panel’s decision was provided in a memorandum report to CADTH. CADTH has prepared a response to address the findings of the procedural review
Outcome: The CDEC Final Recommendation of Do Not Reimburse is upheld for Vraylar.